In adult patients with CKD associated with T2D
CKD=chronic kidney disease; eGFR=estimated glomerular filtration rate; T2D=type 2 diabetes.
*If serum potassium levels are >4.8 to 5.0 mEq/L, initiation may be considered with additional potassium monitoring within the first 4 weeks based on clinical judgment and serum potassium levels.1
†If eGFR has decreased by more than 30% compared to previous measurement, maintain 10-mg dose.1
Monitor serum potassium 4 weeks after a dose adjustment, and throughout treatment, and adjust the dose as needed.1
eGFR=estimated glomerular filtration rate.
KERENDIA is indicated to reduce the
risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D)
Measure serum potassium periodically during treatment with KERENDIA and adjust dose accordingly. More frequent monitoring may be necessary for patients at risk for hyperkalemia, including those on concomitant medications that impair potassium excretion or increase serum potassium
Please read the Prescribing Information for KERENDIA.
References: 1. KERENDIA (finerenone) [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals, Inc.; September 2022. 2. Agarwal R, et al. Eur Heart J. 2022;43(6):474-484. doi:10.1093/eurheartj/ehab777.